Company news

Acurx Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on March 18, 2025 Conference Call and Provide Business Update

February 28, 2025

Acurx Announces Publication of Positive Results from an In-Silico Study Predicting the Microbiome-Restorative Potential of Ibezapolstat in the Treatment of CDI

February 24, 2025

JPO Grants Acurx Pharmaceuticals Patent in Japan for DNA Polymerase IIIC Inhibitors

February 19, 2025

Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)

January 5, 2025

Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

January 5, 2025

Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025

December 10, 2024

Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications

December 8, 2024

Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset

November 19, 2024

Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update

November 17, 2024

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update

November 12, 2024

Acurx Announces New Bile Acid and Microbiome Analyses from Ph2b Trial of Ibezapolstat in CDI Patients Presented at IDWeek Scientific Conference

October 20, 2024

Acurx Pharmaceuticals Announces Participation at The Spartan Capital Investor Conference to Showcase Growth Companies and Foster High-Level Investor Engagement

October 16, 2024

Acurx Pharmaceuticals to Discuss Third Quarter 2024 Financial Results on November 13, 2024

October 15, 2024

Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues

September 25, 2024

Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium

September 23, 2024

ACURX PHARMACEUTICALS ANNOUNCES PARTICIPATION AT THE H.C. Wainwright 26th Annual Global Investment Conference

August 25, 2024

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2024 Results and Provides Business Update

August 8, 2024

USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome

July 16, 2024

Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update

July 15, 2024

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference

July 14, 2024

Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update

May 14, 2024

Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection

May 14, 2024

Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference

May 1, 2024

Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference

April 24, 2024

Acurx Pharmaceuticals, Inc. to Discuss First Quarter 2024 Financial Results on May 15, 2024 Conference Call and Provide Business Update

April 22, 2024

Acurx Pharmaceuticals, Inc. Announces Participation in the LD Micro Invitational XIV

March 20, 2024

Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

March 17, 2024

Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update

March 3, 2024

Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development

February 26, 2024

Acurx Announces Positive Extended Clinical Cure Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

January 28, 2024

Acurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024

January 22, 2024

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

January 16, 2024

Acurx to present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure

December 10, 2023

Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update

November 13, 2023

Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection

November 1, 2023

Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update

October 24, 2023

Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences

October 18, 2023

Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection

October 1, 2023

Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress

September 11, 2023

Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023

August 21, 2023

Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update

August 13, 2023

Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update

July 23, 2023

Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023

June 19, 2023

Acurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ET

June 14, 2023

Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering

May 15, 2023

Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update

May 11, 2023

Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update

May 4, 2023

Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference

April 18, 2023

FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference

April 10, 2023

← Newer news releases · Older news releases →

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.